RBM17

Across TCGA pan-cancer cohorts, RBM17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBM17 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM17 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where RBM17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.815	0.950	.015	13	view →
LUAD	DFS	Median	II,III,IV	0.954	0.752	.011	8	view →
PDAC	OS	Quartile	II,III,IV	0.391	0.623	.043	2	view →
LSCC	OS	Median	III,IV	0.776	0.932	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBM17–HNSC (OS)

Open the HNSC breakdown →